Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia.

ABSTRACT: Risk stratification in acute myeloid leukemia (AML) has been extensively improved thanks to the incorporation of recurrent cytogenomic alterations into risk stratification guidelines. However, mortality rates among fit patients assigned to low or intermediate risk groups are still high. Therefore, significant room exists for the improvement of AML prognostication. In a previous work, we presented the Stellae-123 gene expression signature, which achieved a high accuracy in the prognostication of adult patients with AML. Stellae-123 was particularly accurate to restratify patients bearing high-risk mutations, such as ASXL1, RUNX1 and TP53. The intention of the present work was to evaluate the prognostic performance of Stellae-123 in external cohorts using RNAseq technology. For

SUBMITTER: Mosquera Orgueira A 

PROVIDER: S-EPMC9428690 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature